Vertex's kidney disease drug meets main goal in late-stage trial
09/03/2026 20:08
March 9 (Reuters) - Vertex Pharmaceuticals VRTX.O said on Monday that its experimental kidney disease drug met the main goal of a late-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria